9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
Get Help 24/7
logo
Get Help 24/7
mobile logo
Search
 

Archive

25 April
0 Comments
Sticky

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Posted by Goldberg, Persky & White P.C.

Condition Ovarian Neoplasms|Colorectal Neoplasms|Melanoma|Small Cell Lung Cancer|Liposarcoma Estimated Enrollment: 149 Age Group: 19 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: 04-109 Study First Received: August 18, 2005 Last Updated: July 23, 2014 Estimated Primary Completion Date: July 2014 Primary Outcome Measures: apoptotic response Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00132704...

Continue reading
25 April
0 Comments
Sticky

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

Posted by Goldberg, Persky & White P.C.

Condition Tumor Estimated Enrollment: 35 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: PXD101-CLN-4 Study First Received: December 18, 2006 Last Updated: July 7, 2015 Estimated Primary Completion Date: March 2008 Primary Outcome Measures: to determine the maximum tolerated dose of PXD101 administered in combination with 5-FU|to determine whether PXD101 alone can down-regulate thymidylate synthase in patient tumors Sponsors and Collaborators: Onxeo Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00413322...

Continue reading
25 April
0 Comments
Sticky

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Posted by Goldberg, Persky & White P.C.

Condition Solid Tumor|Lymphoma Estimated Enrollment: 121 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: PXD101-CLN-9 Study First Received: December 18, 2006 Last Updated: July 7, 2015 Estimated Primary Completion Date: August 2011 Primary Outcome Measures: Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohort|Determine the pharmacokinetics of oral PXD101 when dosed once or twice daily at various dose levels|Explore anti-tumor activity|Determine the safety, tolerability, and anti-tumor activity of orally administered PXD101 to patients with lymphoma Sponsors and Collaborators: Onxeo|Spectrum Pharmaceuticals, Inc Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00413075...

Continue reading
25 April
0 Comments
Sticky

E-MOSAIC Electronic Tool to Monitor Symptoms

Posted by Goldberg, Persky & White P.C.

Condition Cancer Estimated Enrollment: 264 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Study ID Numbers: SAKK 95/06|EU-20711 Study First Received: May 23, 2007 Last Updated: October 8, 2015 Estimated Primary Completion Date: January 2012 Primary Outcome Measures: Determine the effect of an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC) and a Longitudinal Monitoring Sheet (LoMoS) on global quality of life (G-QOL)|Determine if this tool affects communication between these patients and their treating physicians.|Determine if this tool affects the symptoms and syndromes reported by these patients|Determine if this tool impacts symptom management performance Sponsors and Collaborators: Swiss Group for...

Continue reading
25 April
0 Comments
Sticky

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

Posted by Goldberg, Persky & White P.C.

Condition Cancer Estimated Enrollment: null Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000270801|MSKCC-02080|NCI-1617 Study First Received: March 6, 2003 Last Updated: April 23, 2011 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00055705...

Continue reading
25 April
0 Comments
Sticky

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Posted by Goldberg, Persky & White P.C.

Condition Cancer Estimated Enrollment: 75 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 010124|01-C-0124|NCI-2792|CDR0000068615 Study First Received: July 11, 2001 Last Updated: March 14, 2012 Estimated Primary Completion Date: April 2008 Primary Outcome Measures: Dose-limiting toxicities and maximum tolerated dose|Pharmacology and pharmacokinetics|Acetylation of histones in peripheral blood|Tumor response by CT scan every 12 weeks Sponsors and Collaborators: National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00020579...

Continue reading
25 April
0 Comments
Sticky

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Posted by Goldberg, Persky & White P.C.

Condition Advanced Solid Tumors Estimated Enrollment: 60 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: OSI-930-103 Study First Received: December 26, 2007 Last Updated: September 26, 2011 Estimated Primary Completion Date: April 2010 Primary Outcome Measures: Determine the maximum tolerated dose (MTD), evaluate the pharmacokinetic profiles|Safety, evaluate pharmacodynamic relationships Sponsors and Collaborators: Astellas Pharma Inc|OSI Pharmaceuticals Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00603356...

Continue reading
25 April
0 Comments
Sticky

Rigid Thoracoscopy Versus CT-Guided Pleural Needle Biopsy

Posted by Goldberg, Persky & White P.C.

Condition Pleural Effusion|Pleural Diseases Estimated Enrollment: 124 Age Group: 18 Years to 85 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Primary Purpose: Diagnostic Study ID Numbers: 2007.11.008 Study First Received: July 21, 2008 Last Updated: July 22, 2008 Estimated Primary Completion Date: June 2008 Primary Outcome Measures: Efficacy and safety of both thoracoscopy and CT-guided pleural needle biopsy for diagnosis of pleural diseases|Determine the efficacy of pleural needle biopsy and thoracoscopy in relation to CT findings. Sponsors and Collaborators: Eskisehir Osmangazi University Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00720954...

Continue reading
25 April
0 Comments
Sticky

Rapamycin With Grapefruit Juice for Advanced Malignancies

Posted by Goldberg, Persky & White P.C.

Condition Tumors|Neoplasm Metastasis Estimated Enrollment: 41 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 14435B Study First Received: September 11, 2006 Last Updated: January 16, 2014 Estimated Primary Completion Date: May 2009 Primary Outcome Measures: Pharmacokinetic interaction Sponsors and Collaborators: University of Chicago Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00375245...

Continue reading
25 April
0 Comments
Sticky

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Posted by Goldberg, Persky & White P.C.

Condition Life Threatening Diseases Estimated Enrollment: 185 Age Group: 15 Years to 70 Years   (Child, Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CSTI571B2225 Study First Received: September 9, 2005 Last Updated: November 16, 2016 Estimated Primary Completion Date: January 2007 Primary Outcome Measures: To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases|To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease|To assess the safety and tolerability of Imatinib mesylate|To evaluate the pharmacokinetic profile of Imatinib mesylate|To assess,...

Continue reading